A different look at the management of chronic hepatitis B in a resource-constrained country

摘要

Chronic hepatitis B (CHB) poses a serious public health burden in Asian-Pacific countries including China [1]. To promote communication between hepatologists in China and outside of the world, epidemiology, prevention, diagnosis and management of CHB in China were published in a special supplement of JVH in 2010 [2]. Today, treatment for CHB is still an enormous challenge in China, although the prevalence of HBsAg in general population has declined from 9.75% to 7.18% due to successful universal HBV vaccination in newborns [1]. Because most patients who receive NA may require long-term therapy to prevent the progression of liver disease, both American and European guidelines recommend ente-cavir and tenofovir as first-line oral agents due to their potent antiviral effect and low risk of drug resistance [3,4].